FDA Places Orthopedic Selection Tool in Class II Category
Published Date: 4/16/2026
Rule
Summary
The FDA is officially putting the manual surgical tool used to pick the right patients for orthopedic implants into a safer, more controlled category called Class II. This change helps make sure the tool works well and is safe, while also making it easier for new, helpful devices to reach patients faster. The new rules took effect on April 16, 2026, and could save time and money by cutting unnecessary red tape.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Class II listing could speed patient access
The FDA classified the manual surgical instrument for selecting patients for orthopedic implants as Class II (special controls). This final order is effective April 16, 2026, and the FDA says classifying the device into Class II will enhance patients' access to beneficial innovations in part by reducing regulatory burdens.
New special controls manufacturers must meet
Manufacturers of this instrument must meet special controls that include validated technical specifications for instrument geometry, validation that use does not alter patient anatomy, biocompatibility of patient-contacting parts, and labeling that names validated implant/instrument pairings and reprocessing instructions. Those controls are codified at 21 CFR 888.4510 as part of the Class II requirements.
Device remains subject to 510(k) premarket review
The final order states this device is subject to premarket notification under section 510(k) of the FD&C Act. FDA also notes it may, at a future date, publish a separate notice announcing intent to exempt this device type from 510(k) requirements.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-07366 — Physical Medicine Devices; Reclassification of Non-Invasive Bone Growth Stimulators
The FDA is changing the rules for non-invasive bone growth stimulators, moving them from the strictest category (Class III) to a less strict one (Class II) with special safety checks. This means companies will have an easier, faster path to get these devices approved, starting May 18, 2026. Patients and makers of these devices can expect safer products without big delays or extra costs.
Next: 2026-07396 — National Emission Standards for Hazardous Air Pollutants: Coal- and Oil-Fired Electric Utility Steam Generating Units: Final Repeal; Correction
The EPA fixed some typos and missing bits in a recent rule that cancels certain pollution limits for coal- and oil-fired power plants. These corrections don’t change the rule itself, which starts on April 27, 2026, and mainly affect power plants and the environment. No new costs or deadlines—just making sure the paperwork is crystal clear!